Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD34+/CD105+ cells are enriched in primitive circulating progenitors residing in the G0 phase of the cell cycle and contain all bone marrow and cord blood CD34+/CD38low/- precursors.
Pierelli L, Scambia G, Bonanno G, Rutella S, Puggioni P, Battaglia A, Mozzetti S, Marone M, Menichella G, Rumi C, Mancuso S, Leone G. Pierelli L, et al. Among authors: leone g. Br J Haematol. 2000 Mar;108(3):610-20. doi: 10.1046/j.1365-2141.2000.01869.x. Br J Haematol. 2000. PMID: 10759721 Free article.
Peripheral blood progenitor cell collection after epirubicin, paclitaxel, and cisplatin combination chemotherapy using EPO-based cytokine regimens: a randomized comparison of G-CSF and sequential GM-/G-CSF.
Perillo A, Pierelli L, Scambia G, Serafini R, Paladini U, Salerno MG, Bonanno G, Fattorossi A, Leone G, Mancuso S, Menichella G. Perillo A, et al. Among authors: leone g. Transfusion. 2001 May;41(5):674-80. doi: 10.1046/j.1537-2995.2001.41050674.x. Transfusion. 2001. PMID: 11346705 Clinical Trial.
High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration.
Benedetti Panici P, Pierelli L, Scambia G, Foddai ML, Salerno MG, Menichella G, Vittori M, Maneschi F, Caracussi U, Serafini R, Leone G, Mancuso S. Benedetti Panici P, et al. Among authors: leone g. Br J Cancer. 1997;75(8):1205-12. doi: 10.1038/bjc.1997.206. Br J Cancer. 1997. PMID: 9099971 Free PMC article. Clinical Trial.
Expansion of granulocyte colony-stimulating factor/chemotherapy-mobilized CD34+ hematopoietic progenitors: role of granulocyte-macrophage colony-stimulating factor/erythropoietin hybrid protein (MEN11303) and interleukin-15.
Pierelli L, Scambia G, Bonanno G, Coscarella A, De Santis R, Mele A, Battaglia A, Fattorossi A, Romeo V, Menichella G, Mancuso S, Leone G. Pierelli L, et al. Among authors: leone g. Exp Hematol. 1999 Mar;27(3):416-24. doi: 10.1016/s0301-472x(98)00056-3. Exp Hematol. 1999. PMID: 10089903 Free article.
Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison.
Pierelli L, Perillo A, Greggi S, Salerno G, Panici PB, Menichella G, Fattorossi A, Leone G, Mancuso S, Scambia G. Pierelli L, et al. Among authors: leone g. J Clin Oncol. 1999 Apr;17(4):1288. doi: 10.1200/JCO.1999.17.4.1288. J Clin Oncol. 1999. PMID: 10561191 Clinical Trial.
1,353 results